Head and Neck Cancer
An Introduction to Head and Neck Cancer
More than 60% of patients with squamous cell cancer of the head and neck present with stage III or IV disease, which has a poor prognosis. However, recent advances have improved outcomes. Chemoradiotherapy is often successful in first-line treatment and more precisely targeted radiotherapy using intensity-modulated radiation therapy, molecular imaging-guided therapy, adaptive therapy and proton beam therapy is expected to decrease the long-term toxicity of radiotherapy. However, recurrent or metastatic disease often develops. Immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1) have proved effective for a minority of patients in this setting and are being investigated in earlier treatment settings.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Head and Neck Cancer Content
Jean Bourhis, ESMO 2019 – Debio 1143 in head and neck cancer
We joined Jean Bourhis at ESMO 2019 to learn a little more about the oral antagonist of inhibitor of apoptosis proteins (IAPs), Debio 1143, which is thought to act as a chemo-radio-sensitizer to enhance treatment efficacy. Questions 1. Please outline the current burden of head and neck cancer? (00:06) 2. Debio 1143 is currently under […]
Mike Gibson, ASCO 2019 – KEYNOTE-062 and KEYNOTE-48 trial data
Editorial Board member, Mike Gibson, reviews data presented at the ASCO 2019 annual meeting around the immune checkpoint inhibitor, pembrolizumab, in the treatment of head and neck cancers. This includes a discussion around KEYNOTE-062 (NCT02494583) and KEYNOTE-48 (NCT02358031) data, the factors that influence the choice of pembrolizumab monotherapy vs pembrolizumab plus chemotherapy and the role […]
Yungan Tao, ESMO 2018 – Developments in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas
In this interview at ESMO 2018, Dr Yungan Tao speaks about the GORTEC 2004-01 randomised phase III trial which looked at 70 Gy/35 F with conventional radiotherapy versus 75 Gy/35 F with intensity-modulated radiotherapy. Dr Tao explains the results and limitations of the study and how this information adds to the body of evidence to […]
Invasive Epiglottic Aspergillosis Mimicking Supraglottic Laryngeal Carcinoma—A Case Report and Review of the Literature
Oncology & Hematology Review, 2016;12(2):97–100 DOI: https://doi.org/10.17925/OHR.2016.12.02.97
Fungal laryngitis is an uncommon condition. The exact incidence is not well defined as very few cases have been reported in the literature. Candida is the most common pathogen involved, with Aspergillus species coming in second.1–3 Other rare causes of fungal laryngitis such as cryptococcosis, blastomycosis, and histoplasmosis have also been reported.4,5 This case report […]
To Hyperfractionate or not to Hyperfractionate – Is it Really a Question?
European Oncology & Haematology, 2016;12(1):19–20 DOI: https://doi.org/10.17925/EOH.2016.12.01.19
The term hyperfractionated radiotherapy (HFR) is used when radiotherapy is delivered in doses below 1.8-2.0 Gy per fraction. The rationale for doing so can be found in the differences in intrinsic radiosensitivity between tumours and late responding normal tissues. A small dose per fraction will tend to increase the therapeutic ratio between tumour and critical […]
Asymptomatic Metastatic Esophageal Cancer Presenting Like Stroke—A Case Report
Oncology & Hematology Review, 2016;12(1):38–40 DOI: https://doi.org/10.17925/OHR.2016.12.01.38
Esophageal cancer is one of the deadliest cancers, and its incidence is on the rise worldwide.1 In the United States, an estimated 16,980 cases of esophageal cancer were diagnosed in 2015 and 15,590 deaths are expected from the disease. With the latest advances in multimodality approaches, the five-year survival rate has risen only to a […]
Mucositis—Supportive Care During Radiotherapy or Chemoradiotherapy of Head and Neck Cancer
Oncology & Hematology Review, 2015;11(1):50–2 DOI: https://doi.org/10.17925/OHR.2015.11.01.50
The majority of patients undergoing radiation therapy for head and neck (HN) cancer will develop oral mucositis, which is a clinical syndrome characterized by erythema, ulcerations, and odynophagia (see Table 1). It is almost universal and more severe among patients with oral cavity, oropharynx, and nasopharynx primaries.1–3 Although therapeutic ratio and outcomes are improved by […]
Head and Neck Cancer Highlights of ESMO Congress 2014
European Oncology & Haematology, 2014;10(2):96–7 DOI: https://doi.org/10.17925/EOH.2014.10.2.96
Despite advances in multimodality treatment, the 5-year survival rate of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) does not exceed 40–50% and survival rates for recurrent or metastatic disease (R/M) remain dismal.1,2 Low survival rates in combination with significant toxicities caused by current treatment strategies used in HNSCC emphasise the necessity […]
Atlas-based Auto-contouring – Balancing Accuracy with Efficiency in OnQ rts®
European Oncology & Haematology, 2014;10(2):98–101 DOI: https://doi.org/10.17925/EOH.2014.10.2.98
Delineation of contours remains the one part of radiotherapy that is completely manual in the majority of centres and therefore the potential for time-saving is huge,1 being estimated to range from 23 %2 to 41 %.3 One of the additional benefits of auto-contouring is the reduction in interobserver variation, which in general is not quantified […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!